Skip to main content
Evidence Snapshot

DNA

CHEMBL2311221 NUCLEIC-ACID Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T18:12:07Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2311221
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats DNA as ChEMBL target CHEMBL2311221. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
DNA
NUCLEIC-ACID · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2311221
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why DNA matters

As of 2026-09-13

DNA is reviewed as DNA; DNA shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 65 linked drugs keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 113 compounds, and 109 assays, with lead potency reaching pChEMBL 10.4.

Disease context
neoplasm

DNA shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 65 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALTRETAMINE, AMINOLEVULINIC ACID HYDROCHLORIDE, AZACITIDINE.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include ALTRETAMINE, AMINOLEVULINIC ACID HYDROCHLORIDE, AZACITIDINE, BUSULFAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 65 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 113 compounds, and 109 assays for this target. The dominant activity type is IC50. CHEMBL5564686 is the current potency anchor at pChEMBL 10.4.

Use CHEMBL5564686 as the tractability anchor when discussing potency (pChEMBL 10.4).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 10.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why DNA matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

113
Total Compounds
109
Total Assays
1
Approved Drugs
IC50: 27.0, KD: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5564686
 10.4 IC50 —
No preferred name
CHEMBL4443767
 8.6 IC50 —
No preferred name
CHEMBL4452530
 6.7 IC50 —
No preferred name
CHEMBL5595301
 5.8 Kd —
No preferred name
CHEMBL554551
 5.1 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T18:12:07Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2311221